Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


July 30, 2008 30 July, 2008

Appointment of New Officers


London, Ontario - July 30, 2008 - Sernova Corp. (TSX-V: SVA)

Sernova is pleased to announce that Craig Gauld has been appointed as Executive Vice President. Mr. Gauld holds science and law degrees from the University of Western Ontario, and brings over 20 years experience in management, law, finance and administration in the international biotechnology and technology sectors. Mr. Gauld will be replacing current Executive Vice President Phil Morehouse who has resigned effective May 15, 2008 to pursue private business opportunities.

Sernova is also pleased to announce the appointment of William G. Smethurst as Chief Financial Officer. Mr. Smethurst is a Chartered Accountant with over 25 years experience, starting at Coopers & Lybrand and progressing into senior management positions in the finance, leasing, energy and biotechnology sectors. His expertise includes finance, operations and business development in the private and public sectors. Mr. Smethurst is replacing Patrick Groening who resigned as CFO as of June 30, 2008.

Justin Leushner, President of Sernova, said: "These two appointments have allowed us to consolidate the management of the company in London, Ontario where our research laboratories are located. Craig and Bill bring many years of international biotechnology experience which will be important as we advance to clinical trials of our lead Sertolin product for diabetes."

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: Tel: (519) 858-5126 info@sernova.com www.sernova.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.